We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

25 hedge funds and large institutions have $5.97M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.49% less ownership

Funds ownership: 6% → 3.51% (-2.5%)

25% less call options, than puts

Call options by funds: $3.2M | Put options by funds: $4.3M

26% less funds holding

Funds holding: 34 → 25 (-9)

57% less capital invested

Capital invested by funds: $13.8M → $5.97M (-$7.79M)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
25
Holders Change
-9
Holders Change %
-26.47%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
7
Closed
11
Calls
$3.2M
Puts
$4.3M
Net Calls
-$1.09M
Net Calls Change
+$1.58M

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$498K
2
Jane Street
Jane Street
New York
+$491K
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$18K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$2.83M
2
VF
Virtu Financial
New York
-$1.59M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$931K
4
BRC
Bell Rock Capital
Delaware
-$678K
5
Koshinski Asset Management
Koshinski Asset Management
Illinois
-$263K
Name Holding Trade Value Shares
Change 		Change in
Stake
CIC
1
Chase Investment Counsel
Virginia
$1.97M – – –
Jane Street
2
Jane Street
New York
$671K +$491K +10,354 +191%
HF
3
HRT Financial
New York
$663K +$498K +10,513 +207%
SBIA
4
Sheaff Brock Investment Advisors
Indiana
$638K – – –
Citadel Advisors
5
Citadel Advisors
Florida
$591K -$178K -3,757 -21%
CIA
6
Capital Investment Advisors
Georgia
$389K -$23.7K -500 -5%
TFA
7
Toth Financial Advisory
Virginia
$282K -$7.87K -166 -2%
TRCT
8
Tower Research Capital (TRC)
New York
$202K -$2.83M -59,730 -93%
BNP Paribas Financial Markets
9
BNP Paribas Financial Markets
France
$84.8K +$18K +380 +24%
CAL
10
Capital Analysts LLC
Pennsylvania
$73K – – –
VFA
11
Valeo Financial Advisors
Indiana
$70K – – –
UBS Group
12
UBS Group
Switzerland
$68K -$18.1K -381 -19%
Morgan Stanley
13
Morgan Stanley
New York
$55K -$27.6K -582 -31%
PNC Financial Services Group
14
PNC Financial Services Group
Pennsylvania
$49K – – –
ASN
15
Advisory Services Network
Georgia
$35K – – –
TC
16
Truvestments Capital
Florida
$32K – – –
EW
17
Evoke Wealth
California
$29.8K +$33.2K +700 New
Simplex Trading
18
Simplex Trading
Illinois
$14K -$30.2K -638 -66%
S
19
SignatureFD
Georgia
$13K – – –
AG
20
Advisor Group
Arizona
$9K – – –
CAPTRUST Financial Advisors
21
CAPTRUST Financial Advisors
North Carolina
$8K – – –
GWM
22
Geneos Wealth Management
Colorado
$7K – – –
Citigroup
23
Citigroup
New York
$5K – – –
IA
24
IFP Advisors
Florida
$5K +$5.69K +120 New
LTFS
25
Ladenburg Thalmann Financial Services
Florida
$4K – – –
1
2

BIB Hedge Fund Activity: Q3 2019 in Review

25 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2019, worth a combined $5.97M — down 57% from $13.8M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of BIB and 2 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 3 added.

The largest buyer was HRT Financial, adding an estimated $498K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.83M.

  • 25 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2019, down from 34 in Q2 2019.
  • Funds reported $5.97M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2019, down 57% quarter-over-quarter.
  • 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2019 and 11 closed out, a net change of -9 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2019 was HRT Financial, an estimated $498K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2019 was Tower Research Capital (TRC), an estimated $2.83M sold.

Based on aggregated 13F filings for Q3 2019.